COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients

被引：54

作者：

Chakraborty, Chiranjib ^{[1
,2
]}

Sharma, Ashish Ranjan ^{[2
]}

Bhattacharya, Manojit ^{[2
]}

Sharma, Garima ^{[3
]}

Lee, Sang-Soo ^{[2
]}

Agoramoorthy, Govindasamy ^{[4
]}

机构：

[1] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India

[2] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si, Gangwon Do, South Korea

[3] Kangwon Natl Univ, Coll Pharm, Neuropsychopharmacol & Toxicol Program, Chunchon, South Korea

[4] Tajen Univ, Coll Pharm & Hlth Care, Pingtung 907, Taiwan

来源：

JOURNAL OF MEDICAL VIROLOGY | 2020年 / 92卷 / 11期

关键词：

cytokine storm; IL-6R antagonist; sarilumab; therapeutic option; tocilizumab;

D O I：

10.1002/jmv.26078

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL-6R) antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL-6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL-6R antagonists for the therapy of cytokine storm syndrome severe acute respiratory syndrome coronavirus 2 infected persons to enhance the therapeutic options for cytokine storm.

引用

页码：2260 / 2262

页数：3

共 50 条

[1] The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, Ana
Smibert, Olivia
Gibson, Andrew
Phillips, Elizabeth J.
Trubiano, Jason A.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (03) : 518 - +
[2] SARS-CoV-2: Cytokine Storm and Therapy
Sajid, Mir Ibrahim
Tariq, Javeria
Awais, Shehar Bano
Naseem, Zehra
Balouch, Samira Shabbir
Abaidullah, Sajid
[J]. ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2020, 26 : 243 - 251
[3] IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19 Who, When, and How?
Matthay, Michael A.
Luetkemeyer, Anne F.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (06): : 483 - 485
[4] Study presence of COVID-19 (SARS-CoV-2) in the sweat of patients infected with Covid-19
Fathizadeh, Hadis
Taghizadeh, Sepehr
Safari, Rohollah
Khiabani, Saeid Shabestari
Babak, Bayaz
Hamzavi, Fatemeh
Ganbarov, Khudaverdi
Esposito, Silvano
Zeinalzadeh, Elham
Dao, Sounkalo
Kose, Sukran
Kafil, Hossein Samadi
[J]. MICROBIAL PATHOGENESIS, 2020, 149
[5] Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?
A. Berni
D. Malandrino
G. Parenti
M. Maggi
L. Poggesi
A. Peri
[J]. Journal of Endocrinological Investigation, 2020, 43 : 1137 - 1139
[6] Enhancement of IL-6 Production Induced by SARS-CoV-2 Nucleocapsid Protein and Bangladeshi COVID-19 Patients' Sera
Hasan, Abu
Rahim, Rummana
Nakayama, Emi E.
Uno, Kazuko
Hasan, Nazmul
Rahman, Mizanur
Shioda, Tatsuo
[J]. VIRUSES-BASEL, 2023, 15 (10):
[7] Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?
Berni, A.
Malandrino, D.
Parenti, G.
Maggi, M.
Poggesi, L.
Peri, A.
[J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2020, 43 (08) : 1137 - 1139
[8] Cytokine storm syndrome in SARS-CoV-2: a review
Wahid, Braira
Rani, Noshaba
Idrees, Muhammad
[J]. ZEITSCHRIFT FUR NATURFORSCHUNG SECTION C-A JOURNAL OF BIOSCIENCES, 2022, 77 (1-2): : 65 - 69
[9] Is IL-6 a key cytokine target for therapy in COVID-19?
Simon A. Jones
Christopher A. Hunter
[J]. Nature Reviews Immunology, 2021, 21 : 337 - 339
[10] Is IL-6 a key cytokine target for therapy in COVID-19?
Jones, Simon A.
Hunter, Christopher A.
[J]. NATURE REVIEWS IMMUNOLOGY, 2021, 21 (06) : 337 - 339

← 1 2 3 4 5 →